{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:16:07Z","timestamp":1777666567998,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hum Exp Toxicol"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:p>\n                    Sibutramine mesylate is a new anti-obesity drug. It is a crystalline salt of sibutramine developed to improve the solubility of sibutramine hydrochloride. Methanesulfonic acid was used as a salt-forming acid instead of hydrochloric acid, resulting in a greatly improved solubility of 1000 mg\/mL in water. Sibutramine mesylate was administered orally to ICR mice, Sprague\n                    <jats:sup>\/<\/jats:sup>\n                    respiratory system and the other organ systems. Following administration of sibutramine mesylate, spontaneous locomotor activity was significantly increased from 120 min to 24 hours at 3.45 mg\/kg and from 30 min to 24 hours at 11.50 mg\/kg. Furthermore, there were a decrease in hexobarbitalinduced sleep time, an increase in respiratory rate at 120 min, increases in intestinal transport capacity and gastric pH at 11.50 mg\/kg, and decreases in gastric\n                    <jats:sup>\/<\/jats:sup>\n                    Dawley rats, and beagle dogs at dose levels of 1.15, 3.45, and 11.50 mg\/kg to measure its effects on the central nervous system (CNS), general behaviour, cardiovascular volume and total acidity at 3.45 and 11.50 mg\/kg. However sibutramine mesylate caused no effects on general behaviour, motor coordination, body temperature, analgesia, convulsion, blood pressure, heart rate, electrocardiogram, cardiac functions of the isolated rat heart, isolated smooth muscles and renal function. Based on the above results, it was concluded that sibutramine mesylate caused effects on the spontaneous locomotor activity, hexobarbital-induced sleep time, respiration, gastrointestinal transport, and gastric secretion at a dose level of 3.45 mg\/kg or greater but caused no effects on other general pharmacological reactions.\n                  <\/jats:p>","DOI":"10.1191\/0960327105ht510oa","type":"journal-article","created":{"date-parts":[[2005,4,15]],"date-time":"2005-04-15T23:13:54Z","timestamp":1113606834000},"page":"109-119","source":"Crossref","is-referenced-by-count":11,"title":["Safety pharmacology of sibutramine mesylate, an anti-obesity drug"],"prefix":"10.1177","volume":"24","author":[{"given":"Eun-Joo","family":"Kim","sequence":"first","affiliation":[{"name":"Korea Institute of Toxicology, KRICT, 100 Jang-Dong, Yuseong, Daejeon,                         South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Kyung","family":"Park","sequence":"additional","affiliation":[{"name":"Korea Institute of Toxicology, KRICT, Yusong, Taejon, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwee-Hyun","family":"Suh","sequence":"additional","affiliation":[{"name":"Hanmi Pharmaceutical Company, Ltd., Bundang, Kyeonggi-do, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,3,1]]},"reference":[{"key":"atypb1","volume-title":"Obesity: Preventing and Managing the Global Epidemic","author":"World Health Organization","year":"1998"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00006"},{"key":"atypb3","first-page":"515","volume":"101","author":"Cheerthan SC","year":"1990","journal-title":"Br J Pharmacol"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(89)90048-8"},{"issue":"1","key":"atypb5","first-page":"S25","volume":"21","author":"Stock MJ","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"atypb6","unstructured":"6                      Physician's Desk Reference (PER)                 . Meridiafi,57thedition.                      Abbott Park, IL: Abbott Laboratories                 , 2003: 475-475."},{"key":"atypb7","unstructured":"7                      Merck Index                 .                      Sibutramine                 ,13th edition, Merck&Co., Inc. 2001: 1522-1522."},{"key":"atypb8","volume-title":"Reductil [package insert]","year":"2000"},{"key":"atypb9","unstructured":"9                      Irwin S                 . In                      Nodine JH                 ,                      Siegler PE                 . Animal and clinical pharmacologic techniques in drug evaluation.                      Yearbook Medical Publishers: Chicago                 , 1964: 36\u201354."},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403689"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1002\/jps.3030460322"},{"key":"atypb12","first-page":"412","volume":"18","author":"Koster R","year":"1959","journal-title":"Fed Proc"},{"key":"atypb13","first-page":"319","volume":"106","author":"Swinyard EA","year":"1952","journal-title":"J Pharmacol Exp Therap"},{"key":"atypb14","first-page":"97","volume":"92","author":"Woodbury LA","year":"1592","journal-title":"Arch Int Pharmacodyn"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1538\/expanim.51.465"},{"key":"atypb16","first-page":"299","volume":"45","author":"Truett AA","year":"1995","journal-title":"Laboratory Animal Science"},{"key":"atypb17","first-page":"R541","volume":"270","author":"Trutt AA","year":"1996","journal-title":"Am J Physiology"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90471-7"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00054747"},{"key":"atypb20","first-page":"43","volume":"5","author":"Shay H","year":"1945","journal-title":"Gastroenterology"},{"key":"atypb21","volume-title":"The United States Patent Application Publication (Pub. No.: US 2004\/0068018 A1)","author":"Lee JH","year":"2004"},{"key":"atypb22","first-page":"30","volume":"22","author":"Astrup A","year":"1998","journal-title":"Int J Obes Rela Metab Disord"},{"key":"atypb23","unstructured":"23                      Meridia (sibutramine HCL monohydrate, anorexiant\u2013antiobesity)                 . In Compendium of Pharmaceuticals and Specialties,                      Ottawa: Canadian Pharmacist Association 2002: 980\u2013984."},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01423-1"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1212035"}],"container-title":["Human &amp; Experimental Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/0960327105ht510oa","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/0960327105ht510oa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:43:19Z","timestamp":1777448599000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1191\/0960327105ht510oa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1191\/0960327105ht510oa"],"URL":"https:\/\/doi.org\/10.1191\/0960327105ht510oa","relation":{},"ISSN":["0960-3271","1477-0903"],"issn-type":[{"value":"0960-3271","type":"print"},{"value":"1477-0903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}